Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.

Autor: Schulze LL; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Becker E; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Dedden M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Liu LJ; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., van Passen C; Department of Surgery, Division of Molecular and Experimental Surgery, University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Germany., Mohamed-Abdou M; Department of Surgery, Division of Molecular and Experimental Surgery, University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Germany., Müller TM; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany., Wiendl M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Ullrich KAM; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Atreya I; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany., Leppkes M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany., Ekici AB; Institute of Human Genetics, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Kirchner P; Institute of Human Genetics, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany., Stürzl M; Department of Surgery, Division of Molecular and Experimental Surgery, University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Germany., Sexton D; Shire HGT, a Takeda company, Cambridge, MA, USA., Palliser D; Shire HGT, a Takeda company, Cambridge, MA, USA., Atreya R; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany., Siegmund B; Division of Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Neurath MF; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany., Zundler S; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany.

Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2023 Nov 24; Vol. 17 (11), pp. 1817-1832.